Europe’s pharmaceutical cannabis sector is expected to be worth €2.1bn by 2027, with demand in global markets expected to grow as further research is conducted into the medical benefits of cannabis. Northern Leaf targets these rapidly expanding markets, offering high-quality medicinal cannabis to support the manufacture of innovative new therapies.

Operating from a state-of-the-art, 100,000 sq.ft. facility in Jersey, Northern Leaf benefits from a supportive local regulatory regime, high-quality local labour, low energy costs and good agricultural growing conditions.

The Company is one of only two UK growers to hold Home Office, MHRA and EU-GMP accreditations, enabling it to cultivate, grow, harvest and export its product internationally. This combination of regulatory and licensing approvals creates a significant competitive barrier to entry, essential to meet necessary production and operational standards demanded by the sector.

Northern Leaf’s cannabis has already displayed itself as a consistent, high-grade pharmaceutical product after several successful cycles – a pre-requisite for targeting cannabis growth markets and key enabler for commercial success.

The Company’s management and operating team has deep experience and expertise across the pharmaceutical, commercial, political and horticultural sectors. The team is focused on building a sustainably profitable business, scaling operations in line with demand and not ahead of it.